Asthma Market

Global Asthma Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10047
Available Format:

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Drug Class

1.3.2. Market Segmentation by Route of Administration

1.3.3. Market Segmentation by Geography

1.3.4. Analysis Period

1.3.5. Market Data Reporting Unit

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents By region By industry participants By company type

2.3. Market Size Estimation

2.4. Market Breakdown and Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Market Segmentation

4.1.1. Overview by Drug Class Bronchodilators Mast cell stabilizers Leukotriene antagonists Immunosuppressants Combination therapies

4.1.2. Overview by Route of Administration Oral Inhaled Others

4.2. Value Chain Analysis

4.3. Market Dynamics

4.3.1. Trends

4.3.2. Drivers Impact analysis of drivers on market forecast

4.3.3. Restraints Impact analysis of restraints on market forecast

4.3.4. Opportunities

4.4. Porter’s Five Forces Analysis

Chapter 5. Market Size and Forecast by Drug Class

5.1. Bronchodilators

5.2. Mast Cell Stabilizers

5.3. Leukotriene Antagonists

5.4. Immunosuppressants

5.5. Combination Therapies

Chapter 6. Market Size and Forecast by Route of Administration

6.1. Oral

6.2. Inhaled

6.3. Others

Chapter 7. Market Size and Forecast by Geography

7.1. North America Asthma Market

7.1.1. By Drug Class

7.1.2. By Route of Administration

7.1.3. By Country-The U.S and Others

7.2. Europe Asthma Market

7.2.1. By Drug Class

7.2.2. By Route of Administration

7.2.3. By Country –Germany, Spain, France, Italy and Rest of Europe

7.3. Asia-Pacific Asthma Market

7.3.1. By Drug Class

7.3.2. By Route of Administration

7.3.3. By Country -China, Japan, India and Rest of Asia-Pacific

7.4. Latin America Asthma Market

7.4.1. By Drug Class

7.4.2. By Route of Administration

7.4.3. By Country -Brazil, Mexico and Rest of Latin America

7.5. Middle East and Africa (MEA) Asthma Market

7.5.1. By Drug Class

7.5.2. By Route of Administration

7.5.3. By Country -South Africa and Rest of MEA

Chapter 8. Competitive Landscape

8.1. Competitive Analysis of Key Players

8.2. Global Strategic Developments

Chapter 9. Company Profiles

9.1. GlaxoSmithKline plc

9.1.1. Business Overview

9.1.2. Product and Service Offerings

9.1.3. Key Financial Summary

9.1.4. Strategic Growth Plan

9.2. Merck & Co., Inc.

9.2.1. Business Overview

9.2.2. Product and Service Offerings

9.2.3. Key Financial Summary

9.2.4. Strategic Growth Plan

9.3. AstraZeneca plc

9.3.1. Business Overview

9.3.2. Product and Service Offerings

9.3.3. Key Financial Summary

9.3.4. Strategic Growth Plan

9.4. Novartia AG

9.4.1. Business Overview

9.4.2. Product and Service Offerings

9.4.3. Key Financial Summary

9.4.4. Strategic Growth Plan

9.5.  F. Hoffmann La-Roche Ltd. 

9.5.1. Business Overview

9.5.2. Product and Service Offerings

9.5.3. Key Financial Summary

9.5.4. Strategic Growth Plan

9.6.  Teva Pharmaceutical Industries Ltd.

9.6.1. Business Overview

9.6.2. Product and Service Offerings

9.6.3. Key Financial Summary

9.6.4. Strategic Growth Plan

9.7. Boehringer Ingelheim GmbH

9.7.1. Business Overview

9.7.2. Product and Service Offerings

9.7.3. Key Financial Summary

9.7.4. Strategic Growth Plan

9.8. Sunovion Pharmaceuticals Inc.

9.8.1. Business Overview

9.8.2. Product and Service Offerings

9.8.3. Key Financial Summary

9.8.4. Strategic Growth Plan

9.9. Ono Pharmaceutical Co., Ltd.

9.9.1. Business Overview

9.9.2. Product and Service Offerings

9.9.3. Key Financial Summary

9.9.4. Strategic Growth Plan

9.10. Koninklijke Philips N.V.

9.10.1. Business Overview

9.10.2. Product and Service Offerings

9.10.3. Key Financial Summary

9.10.4. Strategic Growth Plan

*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.

Chapter 10. Appendix

10.1. Abbreviations

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry